-- Announced positive topline data from pivotal Phase III ADVOCATE trial for ANCA-vasculitis in Q4;  U.S. NDA filing expected mid-2020 -- -- “2020 4-Sight” on the horizon with topline data from four clinical trials expected in 2020: AURORA and ACCOLADE clinical trials of avacopan in Hidradenitis

MOUNTAIN VIEW, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2019 financial results will be released after market close on Tuesday, March 10, 2020. ChemoCentryx executive management will host a

MOUNTAIN VIEW, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Wednesday, February 26, 2020 at 3:00 p.m. ET .

Non-dilutive funding vehicle strengthens balance sheet for registration filing of avacopan in ANCA vasculitis and anticipated approval and commercial launch MOUNTAIN VIEW, Calif. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (NASDAQ: CCXI) today announced that the Company has secured a

MOUNTAIN VIEW, Calif. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednesday January 15, 2020 at 1:30 p.m. PT .

MOUNTAIN VIEW, Calif. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 2:30 p.m. ET .

-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks --   -- Significantly reduced glucocorticoid toxicity -- -- Significantly improved kidney function compared to glucocorticoid-containing SOC

-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ACCOLADE Phase II Trial in C3G -- Reinforces Therapeutic Potential of Chemokine Receptor 2 (CCR2) Inhibition in the Treatment of FSGS -- MOUNTAIN VIEW, Calif. , Nov.

-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA vasculitis expected mid-to-late fourth quarter -- -- Awarded $1 million grant from the U.S. Food and Drug Administration ( FDA ), to support the ACCOLADE Phase II trial of avacopan in C3 Glomerulopathy

MOUNTAIN VIEW, Calif. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2019 financial results will be released after market close on Monday, November 4, 2019 . ChemoCentryx executive management will host a conference call and